The data provided here suggests that tumoral activin is associated with increased expression of proliferation, immunosuppression, and CAF activation suggesting that targeting activin may be effective in multiple forms of CRC regardless of mutations and MSI/MSS status. Here, INHBE is linked to colorectal carcinoma.